Founded in 1989, it is a modern enterprise specializing in high-quality soft capsules, focusing on product development/production/retail in the field of pharmaceutical and health industry
Shenzhen Neptunus Group Co., Ltd. (hereinafter referred to as Neptunus Group) was founded in Shenzhen in 1989. Over the past 27 years, Neptunus Group has focused on the pharmaceutical and health industry, insisted on taking innovation as the fundamental driving force for enterprise development, and has become a large-scale backbone enterprise with a relatively complete industrial chain, strong independent innovation ability and outstanding business model innovation ability in China's pharmaceutical and health industry. It has three listed companies, namely "Neptunus Biotech" listed on the A-share market, "Neptunus Interlon" listed on the Hong Kong Growth Enterprise Market and "Neptune Xingchen" listed on the New York Stock Exchange. In 2015, the group's sales scale reached 28 billion yuan, profits and taxes exceeded 2.5 billion yuan, and the number of employees was 31,500, ranking among the top in China's pharmaceutical industry in terms of comprehensive strength.
Leading brand value - The "Neptunus" brand created by Neptunus Group is the most influential brand in China's pharmaceutical and health industry, ranking first in the brand value of China's pharmaceutical industry for 13 consecutive years. In 2016, the brand value of "Neptune" reached 44.785 billion yuan (World Brand Laboratory).
Outstanding innovation ability - Neptunus Group has the leading independent innovation ability of pharmaceutical products in China and a complete R&D system. It has national R&D platforms such as "National Technology Center", "National High-tech Research and Development Program Achievement Industrialization Base", and postdoctoral research workstations. It is one of the few pharmaceutical companies in China with the ability to develop a class of new drugs, and has achieved a major breakthrough in the field of a class of new drug research and development.
Fruitful results in business model innovation - through business model innovation, Neptunus Group's pharmaceutical business and chain pharmacy business have developed rapidly. In 2015, the sales scale of pharmaceutical commercial circulation exceeded 13 billion, and the network covers North China, East China, Northeast China and other regions. Neptune chain pharmacy is the largest directly operated chain pharmacy in China, covering more than 70 large and medium-sized cities in China, with 2,000 directly-operated stores, and its sales scale and tax payment have been in the forefront of the industry for many years.
Industrial-level innovation strategy - At present, Neptunus Group is making every effort to promote the industrial-level innovation strategy in the two major fields of drug supply and health care products in public hospitals with the supply-side reform model, and rapidly build a 100-billion-level pharmaceutical and health innovation industry.
In view of the current situation of inflated drug prices and administrative regulation and control failure in public hospitals in China, Neptunus Group actively responds to the national policy of reducing inflated drug prices, innovates the drug supply model of public hospitals with Internet thinking, and creates a new drug market pricing and supply mechanism. This project is a major strategic innovation project to change the status quo of the pharmaceutical industry, and is expected to achieve a market size of 100 billion yuan in about three years.
In the field of health care products, Neptunus Group's "big health care strategy" has entered the implementation stage. Neptunus subverted the traditional pricing system, cut off more than 80% of the inflated pricing, cut all circulation costs, and created the lowest cost with 100 billion production capacity to benefit the people. To make health care products that everyone in China can afford to eat and can trust. To build China's largest and world-class health care products industry, and achieve a market scale of 100 billion yuan in about three years.
Development goal - During the 13th Five-Year Plan period, the health industry will usher in explosive growth. Neptunus Group will take advantage of the momentum, focus on the pharmaceutical and health industry, adhere to the equal emphasis on technological innovation and business model innovation, deepen innovation, work hard, and strive to achieve an annual sales scale of more than 200 billion yuan by 2018 and enter the world's top 500.
